After the expiration of the national organization's insulin collection agreement, the bid was opened in Shanghai on the 23rd. More than 35,000 medical institutions from all over the country participated and reported a demand for more than 240 million units of insulin, covering clinically commonly used second-generation and third-generation insulins. The selected price declined steadily. According to the National Health Insurance Administration, a total of 13 companies participated in the successive procurement of 53 products, and 49 products were eligible for selection. All of the bidders were selected for all or part of their products, with a selection rate of 92%. The three-generation pre-mixed group with the largest price difference in the first round of procurement reduced the price difference from 2.3 times to 1.6 times. Market competition was fairer, and corporate supply was more guaranteed. At the same time, the proportion of products selected in Class A with lower prices increased from 40% in the previous round to 71%. Among the products selected in Class A with lower prices, there are products from well-known international companies and major domestic brands, as well as products from newly listed companies.